Correlation between S-1 treatment outcome and expression of biomarkers for refractory thymic carcinoma

BACKGROUND: Thymic carcinoma is a rare cancer with minimal evidence of a survival benefit following chemotherapy. An oral fluoropyrimidine of S-1, however, is the recommended active cytotoxic chemotherapy agent for refractory thymic carcinoma based on a case series, whereas sunitinib or everolimus a...

Descripción completa

Detalles Bibliográficos
Autores principales: Okuma, Yusuke, Hosomi, Yukio, Miyamoto, Shingo, Shibuya, Masahiko, Okamura, Tatsuru, Hishima, Tsunekazu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766615/
https://www.ncbi.nlm.nih.gov/pubmed/26915359
http://dx.doi.org/10.1186/s12885-016-2159-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4766615/
https://www.ncbi.nlm.nih.gov/pubmed/26915359
http://dx.doi.org/10.1186/s12885-016-2159-7

Ejemplares similares